Revenue Growth
Q1 revenue of $75.4 million, up 28% year-over-year and essentially flat sequentially vs Q4 2025 ($76.2M), consistent with expected seasonality.
Strong Free Cash Flow Improvement
Free cash flow of $2.6 million vs negative $5.7 million in prior year, an $8.3 million improvement; trailing twelve-month free cash flow increased to $36.3 million (from $23.3M through 2025 and $11.6M at end of 2024).
Sleep Business Momentum
PAP therapy patient count reached 35,938 (nearly 36,000), up 57% year-over-year and 4% sequentially; resupply patients up 47% year-over-year, driving recurring, predictable revenue.
Maternal Health Expansion and Integration
Lehan integration accretive since acquisition; serviced just under 4,000 new maternal health patients in markets where Lehan previously had no presence, demonstrating scalable platform leverage.
Diversifying Revenue Mix
Ventilator rentals were $35.4M (approx. 47% of revenue) vs 54% in 2025; other HME rentals $16.2M (+25% YoY); equipment & supply sales $17.5M, more than doubling from $7.5M, reducing concentration risk and improving capital efficiency.
Profitability and Margin Progress
Gross profit $42.8M with gross margin of 56.8% (vs 56.3% prior year); adjusted EBITDA $14.3M (19% of revenue). On a comparable basis (excluding a prior-year $2.7M gain), adjusted EBITDA margin expanded ~200 basis points year-over-year.
Operating Cash Flow & CapEx Efficiency
Operating cash flow $8.1M vs $2.9M prior year (nearly 3x); net CapEx $5.5M vs $8.5M prior year; updated full-year net CapEx outlook to 9.0%–10.5% of net revenue (from prior 10%–11.5%).
Strong Balance Sheet & Capital Returns
Ended quarter with $9.8M cash, $46M available credit, long-term debt reduced to $8.3M; repurchased and canceled 150,000 shares for $1.4M and made $3.2M principal debt payments.
Positive Operational Signals in Ventilation
New ventilator setup momentum ahead of expectations: March starts 759 vs 692 a year ago (+~9.7%); compliance among active ventilator patients improved nearly 20% since NCD implementation.
Guidance Update and Confidence
Raised low end of full-year net revenue guidance to $312M–$320M (from $310M–$320M) and reaffirmed adjusted EBITDA guidance of $65M–$69M; expect sequential revenue growth of ~3%–5% per quarter through year.